The right drug,
at the right dose,
first time
Our PGx panel genotypes 30+ pharmacogenes — including CYP2D6, CYP2C19, VKORC1, SLCO1B1, and DPYD — to predict response to 100+ commonly prescribed medications. CPIC- and DPWG-aligned recommendations come with every report.
Built for everyday prescribing decisions
Pharmacogenomic results are most useful when generated before the first prescription that needs them — and they remain valid for life.
Polypharmacy patients
Anyone on three or more chronic medications, where interactions and metabolism stack up.
Mental-health prescribing
SSRIs, SNRIs, and tricyclics route through CYP2D6 and CYP2C19. Knowing metabolizer status shortens trial-and-error cycles.
Cardiovascular care
Clopidogrel, warfarin, and statins all have well-established pharmacogenomic guidance.
Pre-surgical & oncology
DPYD before fluoropyrimidines, TPMT before thiopurines, UGT1A1 before irinotecan — high-risk drug-gene pairs.
How a result reads on this panel
Below is an illustrative example of the matrix layout we use in patient and provider reports. Real reports are individualized to the genotyped sample.
| Class · Medication | CYP2C19 | CYP2D6 | CYP2C9 | VKORC1 | SLCO1B1 | TPMT | DPYD | HLA-B | CPIC |
|---|---|---|---|---|---|---|---|---|---|
| Clopidogrelantiplatelet | PM | — | — | — | — | — | — | — | A |
| Warfarinanticoagulant | — | — | IM | IM | — | — | — | — | A |
| Codeineopioid analgesic | — | NM | — | — | — | — | — | — | A |
| Tramadolopioid analgesic | — | IM | — | — | — | — | — | — | A |
| FluoxetineSSRI · antidepressant | NM | PM | — | — | — | — | — | — | A |
| SertralineSSRI · antidepressant | NM | — | — | — | — | — | — | — | A |
| ParoxetineSSRI · antidepressant | — | PM | — | — | — | — | — | — | A |
| AmitriptylineTCA · antidepressant | NM | IM | — | — | — | — | — | — | A |
| Simvastatinstatin · lipid | — | — | — | — | PM | — | — | — | A |
| AtomoxetineADHD · NRI | — | PM | — | — | — | — | — | — | A |
| OmeprazolePPI | IM | — | — | — | — | — | — | — | B |
| Voriconazoleantifungal | PM | — | — | — | — | — | — | — | A |
| Abacavirantiretroviral | — | — | — | — | — | — | — | *57:01 | A |
| Carbamazepineantiepileptic | — | — | — | — | — | — | — | *15:02 | A |
| Allopurinolurate-lowering | — | — | — | — | — | — | — | *58:01 | A |
| Azathioprineimmunosuppressant | — | — | — | — | — | NM | — | — | A |
| 5-Fluorouracilchemotherapy | — | — | — | — | — | — | IM | — | A |
Four phenotypes, plain language
For most pharmacogenes, your two inherited alleles combine into one of four metabolizer phenotypes that drive dosing recommendations.
Ultrarapid
Drug is broken down faster than expected. Standard doses may be ineffective; alternative therapy may be needed.
Normal
Drug metabolism is in the typical range. Standard dosing applies.
Intermediate
Reduced enzyme activity. Dose adjustment or alternate agent may be considered.
Poor
Little or no enzyme activity. Standard doses can be ineffective or toxic — alternative therapy is often warranted.
Prescriber workflow
Once a patient is genotyped, results integrate cleanly into how a prescription is actually written.
Saliva or blood
Sample is collected once and never needs to be repeated.
Lifetime PGx profile
Star-allele calls and metabolizer status across 30+ pharmacogenes.
CPIC-aligned guidance
For every relevant drug, the report cites CPIC and DPWG dosing recommendations.
Future prescriptions
Profile is referenced for every future drug decision over the patient's lifetime.
Bring PGx into your prescribing
Whether you are starting a new medication or routinely optimizing chronic therapy, our PGx team can review your case and route the right report to your provider.